Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

PURPOSE: Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). In the phase 2, open-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Finn, Richard S., Boer, Katalin, Bondarenko, Igor, Patel, Ravindranath, Pinter, Tamas, Schmidt, Marcus, Shparyk, Yaroslav V., Thummala, Anu, Voitko, Nataliia, Bananis, Eustratios, McRoy, Lynn, Wilner, Keith, Huang, Xin, Kim, Sindy, Slamon, Dennis J., Ettl, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383036/
https://www.ncbi.nlm.nih.gov/pubmed/32683565
http://dx.doi.org/10.1007/s10549-020-05755-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383036/
https://www.ncbi.nlm.nih.gov/pubmed/32683565
http://dx.doi.org/10.1007/s10549-020-05755-7

Ejemplares similares